19.08.2020 | COVID-19
Impact of COVID-19 on monitoring of therapeutic unfractionated heparin
Erschienen in: Journal of Thrombosis and Thrombolysis | Ausgabe 3/2021
Einloggen, um Zugang zu erhaltenExcerpt
-
Anti-Xa and aPTT are prone to monitoring inaccuracies in patients with COVID-19 and severe illness.
-
Unexpected thrombosis or bleeding that does not correlate with anti-Xa or aPTT levels may indicate level inaccuracies
-
More research is needed on the monitoring assay to optimize UFH dose titration in COVID-19 patients